GoodRx (NASDAQ:GDRX) Price Target Lowered to $9.00 at Wells Fargo & Company

GoodRx (NASDAQ:GDRXGet Rating) had its price objective reduced by equities researchers at Wells Fargo & Company from $20.00 to $9.00 in a research report issued on Thursday, The Fly reports. Wells Fargo & Company‘s price objective points to a potential upside of 16.28% from the company’s previous close.

A number of other research analysts have also recently weighed in on the stock. Morgan Stanley cut their price objective on shares of GoodRx from $41.00 to $19.00 and set an “equal weight” rating on the stock in a research report on Wednesday, March 2nd. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of GoodRx from $20.00 to $10.00 in a research note on Wednesday. JPMorgan Chase & Co. decreased their target price on shares of GoodRx from $33.00 to $20.00 and set an “underweight” rating for the company in a research report on Tuesday, March 1st. SVB Leerink cut shares of GoodRx from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $33.00 to $10.00 in a report on Tuesday. Finally, Guggenheim assumed coverage on shares of GoodRx in a research note on Wednesday, April 6th. They issued a “buy” rating and a $24.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $24.89.

Shares of NASDAQ:GDRX opened at $7.74 on Thursday. The company’s fifty day moving average price is $16.47 and its 200-day moving average price is $27.30. The firm has a market capitalization of $3.10 billion, a price-to-earnings ratio of -110.56, a PEG ratio of 4.42 and a beta of 0.29. GoodRx has a one year low of $7.33 and a one year high of $48.05. The company has a debt-to-equity ratio of 0.79, a current ratio of 13.42 and a quick ratio of 13.42.

GoodRx (NASDAQ:GDRXGet Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. GoodRx had a negative net margin of 3.39% and a positive return on equity of 0.06%. The company had revenue of $203.30 million during the quarter, compared to analysts’ expectations of $200.61 million. During the same period last year, the company posted ($0.01) EPS. GoodRx’s revenue was up 26.7% on a year-over-year basis. As a group, equities research analysts expect that GoodRx will post 0.17 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. CIBC Asset Management Inc lifted its holdings in GoodRx by 2.4% in the 4th quarter. CIBC Asset Management Inc now owns 16,124 shares of the company’s stock valued at $527,000 after acquiring an additional 376 shares during the last quarter. Rockefeller Capital Management L.P. increased its holdings in shares of GoodRx by 5.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 8,563 shares of the company’s stock valued at $279,000 after purchasing an additional 421 shares during the period. Spire Wealth Management increased its holdings in GoodRx by 50.0% in the fourth quarter. Spire Wealth Management now owns 1,500 shares of the company’s stock worth $49,000 after buying an additional 500 shares during the last quarter. Capital Investment Advisory Services LLC increased its holdings in GoodRx by 5.7% in the fourth quarter. Capital Investment Advisory Services LLC now owns 10,255 shares of the company’s stock worth $335,000 after buying an additional 550 shares during the last quarter. Finally, CWM LLC increased its holdings in GoodRx by 50.2% in the first quarter. CWM LLC now owns 2,224 shares of the company’s stock worth $43,000 after buying an additional 743 shares during the last quarter. 52.60% of the stock is owned by institutional investors.

About GoodRx (Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Read More

The Fly logo

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.